SCHEMBL3520658

SCHEMBL3520658

Cc1ccc(S(OS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)(c2ccc(C)cc2)c2ccc3oc4ccccc4c(=S)c3c2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT1 P54687 1/20 0.36
HTT P42858 4/20 0.36
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CYP1A2 P05177 2/20 0.36
HPGD P15428 2/20 0.36
CYP2C19 P33261 2/20 0.36
GAA P10253 1/20 0.36
LMNA P02545 4/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MAPT P10636 3/20 0.34
MAOB P27338 1/20 0.33
HTR6 P50406 1/20 0.32
PIK3CD O00329 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CB P42338 1/20 0.32
PIK3CG P48736 1/20 0.32
NPSR1 Q6W5P4 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3519676 0.93 HTT (0.37) BCAT1HTTALDH1A1SMN1; SMN2CYP1A2
SCHEMBL3520221 0.92 HTT (0.37) BCAT1HTTALDH1A1SMN1; SMN2CYP1A2
SCHEMBL3519821 0.89 MAOA (0.40) BCAT1HTTALDH1A1SMN1; SMN2CYP1A2
SCHEMBL3519030 0.89 LMNA (0.39) BCAT1HTTALDH1A1SMN1; SMN2CYP1A2
SCHEMBL3521318 0.82 HTT (0.41) BCAT1HTTALDH1A1SMN1; SMN2CYP1A2
SCHEMBL3520236 0.82 BCAT1 (0.42) BCAT1HTTALDH1A1SMN1; SMN2CYP1A2
SCHEMBL3521377 0.82 NPC1 (0.42) HTTALDH1A1SMN1; SMN2CYP1A2HPGD
SCHEMBL3518432 0.81 NPC1 (0.41) HTTALDH1A1SMN1; SMN2CYP1A2HPGD
SCHEMBL3523837 0.80 LMNA (0.40) BCAT1HTTALDH1A1SMN1; SMN2CYP1A2
SCHEMBL3129919 0.78 CA1 (0.41) HTTALDH1A1SMN1; SMN2CYP1A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7833691-B2 Heterocycle-bearing onium salts WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-11-16 US disclosed
EP-1953149-A2 A heterocycle-containing onium salt Wako Pure Chemical Industries, Ltd. (JP) 2008-08-06 EP disclosed
US-20080161520-A1 Heterocycle-bearing onium salts WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2008-07-03 US disclosed
US-7318991-B2 Diphenylsulfonium compounds in which the S atom is additionally attached to a xanthene-9-onyl-2-yl- or coumarin-7-yl- ring; acid generator for a chemically amplified resist; photopolymerization initiator for polymerizing an epoxide or a vinyl ether WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2008-01-15 US disclosed
US-20050233253-A1 Diphenylsulfonium compounds in which the S atom is additionally attached to a xanthene-9-onyl-2-yl- or coumarin-7-yl- ring; acid generator for a chemically amplified resist; photopolymerization initiator for polymerizing an epoxide or a vinyl ether WAKO PURE CHEMICAL INDUSTRIES, LTD (JP) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050233253-A1 Diphenylsulfonium compounds in which the S atom is additionally attached to a xanthene-9-onyl-2-yl- or coumarin-7-yl- ring; acid generator for a chemically amplified resist; photopolymerization initiator for polymerizing an epoxide or a vinyl ether NOX4, CBR1, CBR3 BCAT1 1269/4885HTT 4356/4885ALDH1A1 1190/4885
US-20080161520-A1 Heterocycle-bearing onium salts MCM5, NIT2, PCNA BCAT1 353/4885HTT 50/4885ALDH1A1 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.